PREFERABLE-II PREFERABLE-II - Personalised Exercise-Oncology for improvement of supportive care: a super umbrella trial to demonstrate the (cost)effectiveness of live-remote exercise in cancer survivors
- Coordinator
- Universitair Medisch Centrum Utrecht, Netherlands
- Runs
- 1 November 2022 to 31 October 2027
- Status
- Running
- EU funding
- €5.9m
- Total cost
- €6.0m
- Partners
- 16 organisations in 7 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101057059
What the project is doing
In the project's own words, from its summary on CORDIS.
With over 12 million cancer survivors relying on supportive care across the EU, it is essential to provide them with (cost-)effective interventions tailored to their specific needs. Many survivors suffer from long-term side effects that can lower their quality of life (QoL), functioning, and productivity. Exercise interventions have proven to be uniquely beneficial in managing both physical and psychological complaints.
However, their effects are strongest when tailored to a patient's specific burden, e.g. fatigue, low physical fitness, anxiety and depressive symptoms or chemotherapy-induced peripheral neuropathy. Moreover, the use of exercise interventions in supportive cancer care is still limited due to a lack of availability, a lack of accessibility caused by time and travel constraints and low awareness. To tackle these hurdles, the PREFERABLE-II consortium sets out to design and demonstrate the (cost-)effectiveness of a novel exercise intervention that: 1) will be tailored to the side effect that bothers the survivor the most, by use of a modular design, 2) can be implemented at home, with live-remote supervision from a national broadcast centre, 3) is available to all cancer survivors, and 4) incorporates improved patient-centred communication and shared decision making.
Results of our RCT, enrolling 350 cancer survivors, will be translated into guideline recommendations for exercise-oncology. Extensive ethical, legal and social impact components of the project will reveal barriers and facilitators of live-remote supervised exercise and provide policy recommendations to further support implementation. Finally, we will create communication standards and an education module for healthcare professionals to train the future workforce.
As such, PREFERABLE-II contributes to improving the QoL of cancer survivors by lowering the burden of side effects, while also improving availability, access and awareness off exercise-based supportive care interventions.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Coordinator |
| Cabrini Australia | Malvern | Australia | Associatedpartner |
| European Cancer Patient Coalition | Bruxelles / Brussel | Belgium | Participant |
| Deutsche Sporthochschule Koln | Koln | Germany | Participant |
| Deutsches Krebsforschungszentrum Heidelberg | Heidelberg | Germany | Participant |
| Gottfried Wilhelm Leibniz Universitaet Hannover | Hannover | Germany | Participant |
| Nurogames GmbH | Koln | Germany | Participant |
| Universitatsklinikum Heidelberg | Heidelberg | Germany | Participant |
| Asociacion Instituto De Investigacion Sanitaria Biogipuzkoa | Donostia-San Sebastian | Spain | Participant |
| Asociacion Instituto De Investigacion Sanitaria Biogipuzkoa | Donostia-San Sebastian | Spain | Third party |
| Fundacion Onkologikoa Fundazioa | Donostia San Sebastian | Spain | Participant |
| Servicio Vasco de Salud Osakidetza | Vitoria-Gasteiz | Spain | Third party |
| Julius Clinical Research BV | Zeist | Netherlands | Participant |
| Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis | Amsterdam | Netherlands | Participant |
| Associacao De Investigacao De Cuidados De Suporte Em Oncologia | Vila Nova De Gaia | Portugal | Participant |
| Karolinska Institutet | Stockholm | Sweden | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI